Total Payments
$665.47
2024 Payments
$292.81
Companies
13
Transactions
37
Medicare Patients
5,813
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$619.82 (93.1%)
Education$45.65 (6.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $619.82 | 34 | 93.1% |
| Education | $45.65 | 3 | 6.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $110.88 | 5 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $95.91 | 6 | $0 (2024) |
| Travere Therapeutics, Inc. | $92.57 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $84.14 | 4 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $49.55 | 2 | $0 (2024) |
| Ardelyx, Inc. | $46.85 | 2 | $0 (2024) |
| Lilly USA, LLC | $44.91 | 3 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $37.34 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $31.23 | 2 | $0 (2023) |
| Keryx Biopharmaceuticals, Inc. | $24.37 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $292.81 | 17 | Travere Therapeutics, Inc. ($60.81) |
| 2023 | $191.73 | 11 | AstraZeneca Pharmaceuticals LP ($46.22) |
| 2022 | $89.82 | 5 | Fresenius USA Marketing, Inc. ($37.34) |
| 2021 | $41.80 | 2 | AstraZeneca Pharmaceuticals LP ($41.80) |
| 2019 | $24.94 | 1 | AKEBIA THERAPEUTICS INC ($24.94) |
| 2018 | $24.37 | 1 | Keryx Biopharmaceuticals, Inc. ($24.37) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $15.86 | General |
| 10/14/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Immunology | ||||||
| 09/23/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 08/28/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $4.15 | General |
| 08/20/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Immunology | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.66 | General |
| 07/08/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $10.31 | General |
| 06/11/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: NEPHROLOGY | ||||||
| 05/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Inflammation | ||||||
| 05/13/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 05/13/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $13.60 | General |
| 04/16/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: NEPHROLOGY | ||||||
| 04/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 03/06/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: NEPHROLOGY | ||||||
| 02/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 01/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $14.76 | General |
| 12/05/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 10/31/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $17.00 | General |
| 10/24/2023 | GlaxoSmithKline, LLC. | JESDUVROQ (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: NEPHROLOGY | ||||||
| 10/02/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $23.90 | General |
| 07/10/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: NEPHROLOGY | ||||||
| 06/22/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: NEPHROLOGY | ||||||
| 05/17/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,003 | 2,195 | $888,937 | $249,604 |
| 2022 | 15 | 1,210 | 2,704 | $1.0M | $287,750 |
| 2021 | 15 | 1,551 | 3,940 | $1.2M | $383,816 |
| 2020 | 17 | 2,049 | 4,824 | $1.6M | $432,602 |
Total Patients
5,813
Total Services
13,663
Medicare Billing
$1.4M
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 44 | 265 | $270,300 | $69,043 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 290 | 692 | $176,460 | $58,221 | 33.0% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 20 | 160 | $140,160 | $34,449 | 24.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 41 | 93 | $78,585 | $20,506 | 26.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 67 | 199 | $48,954 | $17,284 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 102 | 102 | $49,776 | $14,635 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 133 | 192 | $33,216 | $11,773 | 35.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 72 | 91 | $43,771 | $11,095 | 25.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 42 | $27,216 | $6,690 | 24.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 23 | 92 | $15,916 | $4,955 | 31.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 188 | 256 | $4,352 | $861.18 | 19.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 11 | $231.00 | $92.40 | 40.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 52 | 386 | $393,720 | $104,252 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 282 | 666 | $159,534 | $56,721 | 35.6% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 24 | 164 | $143,664 | $35,900 | 25.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 42 | 107 | $90,765 | $21,890 | 24.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 54 | 200 | $47,308 | $15,505 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 132 | 197 | $31,961 | $11,805 | 36.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 58 | 72 | $33,352 | $10,726 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $30,668 | $9,733 | 31.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 11 | 43 | $27,864 | $7,237 | 26.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 19 | 96 | $15,768 | $5,400 | 34.2% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 15 | 17 | $12,909 | $2,680 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 16 | $5,325 | $1,952 | 36.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 34 | $5,234 | $1,883 | 36.0% |
About Dr. Gregory Pisel, M.D
Dr. Gregory Pisel, M.D is a Nephrology healthcare provider based in Hickory, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528065604.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Pisel, M.D has received a total of $665.47 in payments from pharmaceutical and medical device companies, with $292.81 received in 2024. These payments were reported across 37 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($619.82).
As a Medicare-enrolled provider, Pisel has provided services to 5,813 Medicare beneficiaries, totaling 13,663 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Hickory, NC
- Active Since 07/05/2005
- Last Updated 05/10/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1528065604
Products in Payments
- FARXIGA (Drug) $110.88
- JYNARQUE (Drug) $95.91
- IBSRELA (Drug) $46.85
- JARDIANCE (Drug) $44.91
- Fabhalta (Drug) $38.58
- Velphoro (Drug) $37.34
- AURYXIA (Drug) $24.94
- Vafseo (Drug) $24.61
- Auryxia (Drug) $24.37
- TAVNEOS (Drug) $18.43
- BENLYSTA (Biological) $15.76
- Veltassa (Drug) $15.72
- JESDUVROQ (Drug) $15.47
- NXSTAGE SYSTEM ONE (Device) $13.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.